Breakthrough aligns with Regeneron’s genomics strategy, signaling acceleration in precision oncology development
PITTSBURGH, May 22, 2025 – Predictive Oncology Inc. (NASDAQ: POAI), a front-runner in artificial intelligence-driven drug discovery, today announced a major technological breakthrough in its PEDAL™ platform, advancing the use of AI and genomics to optimize early-stage oncology research.
Utilizing its vast, clinically annotated biobank of over 150,000 live tumor samples, the company successfully modeled drug response predictions for 21 previously untested compounds across critical cancer types including breast, ovarian, and colorectal. With an impressive accuracy rate exceeding 90%, PEDAL™ enables the identification of promising drug-tumor matches before in vitro testing—offering a smarter, faster path to discovery and preclinical validation.
This scientific leap emerges alongside major industry developments, notably Regeneron Pharmaceuticals’ recent acquisition of 23andMe. The $256 million deal signals a deepening commitment to integrating large-scale genomic insights with AI technologies to accelerate novel therapeutics, echoing the value proposition of platforms like PEDAL™.
Strategic alignment with industry trends
As pharmaceutical leaders pivot toward data-centric development, Predictive Oncology’s achievement underscores the growing consensus: AI-guided, genomics-informed discovery is essential to future innovation in oncology. PEDAL™ stands out by providing a validated, real-world engine for drug prioritization—reducing failure rates and development costs.
Together with Regeneron’s investment in genomic infrastructure, Predictive Oncology’s milestone reflects a broader ecosystem shift toward personalization, speed, and precision in cancer therapy pipelines.
About Predictive Oncology
Predictive Oncology harnesses artificial intelligence, multi-omics data, and one of the world’s most comprehensive live tumor biobanks to revolutionize drug discovery. Its PEDAL™ platform supports biopharma partners by predicting tumor response profiles and optimizing compound selection strategies. Headquartered in Pittsburgh, the company is committed to enabling the next generation of precision oncology treatments.ext generation of precision oncology treatments.
More details: AI Meets Genomics – Predictive Oncology News Release
By